IFUS yields 8492.57% · ABBV yields 3.06%● Live data
📍 IFUS pulled ahead of the other in Year 1
Combined, IFUS + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IFUS + ABBV for your $10,000?
Impact Fusion International, Inc. engages in the business of marketing products in the health and wellness sector. The company focuses on the invention, development, and marketing of its proprietary products worldwide for the health of humans and animals. The company's products include Nutri-Mastic that supports digestive function, the immune system, vital organ health, healthy blood cells, and cardiac muscle and heart function; Intact Nutrition herbal health support products; Intact Endurance, which offers nutrients to increase body's optimal energy levels; Pet Intact nutritional supplements; and Equine Intact products. It also sells herbal health support beverages under the Mastic Blast Beverage brand; and alternative proprietary formulation for beef and dairy cattle under the Supreme Gold Plus brand. The company was formerly known as Red Reef Laboratories International, Inc. and changed its name to Impact Fusion International Inc. in April 2009. Impact Fusion International, Inc. was founded in 2002 and is based in Margate, Florida.
Full IFUS Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.